Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to Covid-19 Pandemic

A Case Series

Bibliographic Data

ID15468447
AuthorsMarianna Mazza (0000-0002-3007-8162, Università Cattolica del Sacro Cuore, corresponding author), Emanuele Caroppo (0000-0001-9602-8208, Azienda Sanitaria Locale Roma 3), Giuseppe Marano (0000-0002-0239-7297, Università Cattolica del Sacro Cuore), Georgios D Kotzalidis (0000-0002-0281-6324, Università Cattolica del Sacro Cuore), Carla Avallone (0000-0003-2664-3023, Università Cattolica del Sacro Cuore), Giovanni Camardese (0000-0002-8139-9230, Università Cattolica del Sacro Cuore), Delfina Janiri (0000-0003-2485-6121, Università Cattolica del Sacro Cuore), Lorenzo Moccia (0000-0003-3176-6060, Università Cattolica del Sacro Cuore), Alessio Simonetti (0000-0002-6963-7494, Università Cattolica del Sacro Cuore), Luigi Janiri (0000-0002-1633-9418, Università Cattolica del Sacro Cuore), Gabriele Sani (0000-0002-9767-8752, Università Cattolica del Sacro Cuore)
Year2022
Volume19
Issue12
Pages7397-7397
Publication date2022-06-16
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph19127397
PMID35742646
OpenAlexW4283072529
LanguageEN
References cited36

(1) Background: During the SARS-CoV-2 (COVID-19) pandemic, cannabis use increased relative to pre-pandemic levels, while forced home confinement frequently caused sleep/wake cycle disruptions, psychological distress, and maladaptive coping strategies with the consequent appearance of anxiety symptoms and their potential impact on substance use problems. (2) Aim: Long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. The present work aims to investigate the effectiveness of trazodone in optimizing the condition of people with cannabis dependence under pandemic conditions. (3) Methods: All cases with cannabis use disorder were uniformly treated with long-acting trazodone 150 mg or 300 mg/day; their craving and clinical status were monitored through appropriate psychometric scales. Side effects were recorded as they were reported by patients. We described the cases of three young patients-one man and two women-who were affected by chronic cannabis use disorder and who experienced lockdown-related psychological distress and sought psychiatric help. (4) Results: The described cases highlight that the once-a-day formulation of trazodone seems to have a therapeutic role in patients with cannabis use disorder and to guarantee tolerability and efficacy over time. No significant side effects emerged. (5) Conclusions: The use of long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. Trazodone deserves to be studied in terms of its efficacy for cannabis use disorder

Addiction · Adverse effect · Antidepressant · Anxiety · Cannabidiol · Cannabis · Cannabis Dependence · Craving · Distress · Psychiatry · Tolerability · Trazodone · Bipolar Disorder and Treatment · Cannabis and Cannabinoid Research · Clinical Psychology · Medicine · Psychology · Sleep and related disorders · Internal Medicine

Citation velocityhistorical
Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae